Boston Scientific Co. (NYSE:BSX) Holdings Reduced by Ecofi Investissements SA

Ecofi Investissements SA lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 19.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 115,300 shares of the medical equipment provider's stock after selling 27,500 shares during the quarter. Boston Scientific makes up approximately 5.9% of Ecofi Investissements SA's portfolio, making the stock its 2nd largest holding. Ecofi Investissements SA's holdings in Boston Scientific were worth $9,542,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. M&T Bank Corp raised its position in shares of Boston Scientific by 0.3% in the third quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider's stock valued at $8,894,000 after purchasing an additional 370 shares during the period. Passumpsic Savings Bank bought a new position in shares of Boston Scientific in the third quarter worth $3,015,000. World Investment Advisors LLC grew its position in shares of Boston Scientific by 50.9% in the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider's stock valued at $979,000 after purchasing an additional 3,939 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $1,175,000. Finally, Tidal Investments LLC boosted its stake in Boston Scientific by 8.8% in the 3rd quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider's stock worth $7,249,000 after purchasing an additional 6,990 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 2.6 %

NYSE:BSX traded up $2.55 during mid-day trading on Thursday, hitting $101.47. 4,273,450 shares of the company's stock traded hands, compared to its average volume of 6,395,588. The company has a fifty day moving average of $98.85 and a 200 day moving average of $94.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a twelve month low of $70.97 and a twelve month high of $107.17. The company has a market capitalization of $150.08 billion, a P/E ratio of 81.03, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. On average, analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays raised their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. BTIG Research restated a "buy" rating on shares of Boston Scientific in a research report on Wednesday. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Wells Fargo & Company upped their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Finally, Evercore ISI upped their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus price target of $112.61.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares in the company, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now owns 5,502 shares of the company's stock, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,009 shares of company stock worth $14,407,381 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.